Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Endocr Pract ; 27(2): 95-100, 2021 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-33551315

RESUMO

OBJECTIVE: To explore the relationship between hyperglycemia in the presence and absence of diabetes mellitus (DM) and adverse outcomes in critically ill patients with coronavirus disease 2019 (COVID-19). METHODS: The study included 133 patients with COVID-19 admitted to an intensive care unit (ICU) at an urban academic quaternary-care center between March 10 and April 8, 2020. Patients were categorized based on the presence or absence of DM and early-onset hyperglycemia (EHG), defined as a blood glucose >180 mg/dL during the first 2 days after ICU admission. The primary outcome was 14-day all-cause in-hospital mortality; also examined were 60-day all-cause in-hospital mortality and the levels of C-reactive protein, interleukin 6, procalcitonin, and lactate. RESULTS: Compared to non-DM patients without EHG, non-DM patients with EHG exhibited higher adjusted hazard ratios (HRs) for mortality at 14 days (HR 7.51, CI 1.70-33.24) and 60 days (HR 6.97, CI 1.86-26.13). Non-DM patients with EHG also featured higher levels of median C-reactive protein (306.3 mg/L, P = .036), procalcitonin (1.26 ng/mL, P = .028), and lactate (2.2 mmol/L, P = .023). CONCLUSION: Among critically ill COVID-19 patients, those without DM with EHG were at greatest risk of 14-day and 60-day in-hospital mortality. Our study was limited by its retrospective design and relatively small cohort. However, our results suggest the combination of elevated glucose and lactate may identify a specific cohort of individuals at high risk for mortality from COVID-19. Glucose testing and control are important in individuals with COVID-19, even those without preexisting diabetes.


Assuntos
COVID-19 , Hiperglicemia , Glicemia , Estado Terminal , Mortalidade Hospitalar , Humanos , Hiperglicemia/epidemiologia , Unidades de Terapia Intensiva , Estudos Retrospectivos , SARS-CoV-2
2.
AACE Clin Case Rep ; 8(2): 78-81, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35415226

RESUMO

Background: Cushing disease (CD) during pregnancy is a rare but serious disease that adversely impacts maternal and fetal outcomes. As the sole use of metyrapone in the management of CD has been rarely reported, we describe our experience of using it to treat a pregnant patient with CD. Case Report: A 34-year-old woman with hypertension was diagnosed with adrenocorticotropic hormone-dependent CD on the basis of a urinary free cortisol (UFC) level of 290 µg/24 h (reference range, 6-42 µg/dL) and an abnormal dexamethasone suppression test (cortisol level, 12.4 µg/dL) before becoming pregnant. She conceived naturally 12 weeks after transsphenoidal surgery and was subsequently found to have persistent disease with a UFC level of 768 µg/dL. Surgery was deemed high-risk given the proximity of the tumor to the right carotid artery and the high likelihood of residual disease. Instead, she was managed with metyrapone throughout her pregnancy and titrated to a goal UFC level of <150 µg/24 h due to the known physiologic increase in the cortisol level during gestation. The patient had diet-controlled gestational diabetes and well-controlled hypertension. She gave birth to a healthy baby boy at 37 weeks of gestation, without adrenal insufficiency in the baby or her. Discussion: This case highlights the successful use of metyrapone throughout pregnancy to manage CD in patients in whom surgery is considered high-risk or in those with a low likelihood of cure. Although metyrapone is effective, close surveillance is required for worsening hypertension, hypokalemia, and potential adrenal insufficiency. Although no fetal adverse events have been reported, this medication crosses the placenta, and the long-term effects are unknown. Conclusion: We describe a case of CD during pregnancy that was successfully treated with metyrapone.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA